News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Auriga Laboratories, Inc. (ARGA.OB) Obtains Rights to Market and Sell a New Product Indicated for the Treatment of ADHD


12/3/2007 11:56:36 AM

LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company, announced today the signing of a license agreement with Outlook Pharmaceuticals, Inc., pursuant to which Auriga will have the exclusive rights to market and sell a new product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the United States. The new product combines one of the most frequently prescribed drug classes for this condition, in a unique dosage form previously not available.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES